Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker BLCO · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Aug 12, 2026 | enVista Envy hydrophobic acrylic intraocular lens (IOL), e… Lens, multifocal intraocular | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Special (Immediate Track) | P240005 ↗ |
| May 15, 2026 | Stellaris Elite vision enhancement system; Posterior and C… | BLCO Bausch and Lomb | Device clearance (510(k)) Special | K261264 ↗ |
| Mar 25, 2026 | Stellaris Elite vision enhancement system (BL11145, BL1445… | BLCO Bausch and Lomb, Incorporated | Device clearance (510(k)) Traditional | K252052 ↗ |
| Jan 20, 2026 | ZIRGAN GANCICLOVIR | BLCO Bausch and Lomb | New drug (NDA), supplement Labeling | NDA022211 ↗ |
| Oct 21, 2025 | MIEBO PERFLUOROHEXYLOCTANE | BLCO Bausch and Lomb Inc | New drug (NDA), supplement Labeling | NDA216675 ↗ |
| Jul 30, 2025 | enVista Envy hydrophobic acrylic intraocular lens (IOL), e… Lens, multifocal intraocular | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P240005 ↗ |
| Jul 1, 2025 | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Labeling | ANDA064065 ↗ |
| Jul 1, 2025 | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Labeling | ANDA064065 ↗ |
| May 22, 2025 | XIPERE TRIAMCINOLONE ACETONIDE | BLCO Bausch and Lomb Inc | New drug (NDA), supplement Labeling | NDA211950 ↗ |
| Apr 8, 2025 | SofLens® Toric (alphafilcon A) Visibility Tinted Contact Le… | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Real-Time Process | P960022 ↗ |
| Apr 4, 2025 | RETISERT FLUOCINOLONE ACETONIDE | BLCO Bausch and Lomb | New drug (NDA), supplement Labeling | NDA021737 ↗ Letter or label ↗ |
| Feb 20, 2025 | Boston Orthokeratology (oprifocon A) Shaping lens for Overn… Lens, contact, orthokeratology, overnight | BLCO Bausch & Lomb | Device approval (PMA), supplement Normal 180 Day Track | P010062 ↗ |
| Feb 18, 2025 | BROMFENAC OPHTHALMIC SOLUTION, PROLENSA BROMFENAC SODIUM | BLCO Bausch and Lomb | New drug (NDA), supplement Labeling | NDA203168 ↗ |
| Jan 14, 2025 | enVista hydrophobic acrylic intraocular lens (IOL), enVista… intraocular lens | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Real-Time Process | P910056 ↗ |
| Jan 14, 2025 | enVista Envy hydrophobic acrylic intraocular lens (IOL), en… Lens, multifocal intraocular | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Real-Time Process | P240005 ↗ |
| Oct 10, 2024 | enVista Envy hydrophobic acrylic intraocular lens (IOL), e… Lens, multifocal intraocular | BLCO Bausch & Lomb, Inc. | Device approval (PMA) | P240005 ↗ |
| Oct 10, 2024 | EyeGility Inserter for Preloaded enVista IOLs | BLCO Bausch & Lomb, Incorporated | Device clearance (510(k)) Traditional | K242389 ↗ |
| Aug 7, 2024 | OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION, EQUATE OLOPA… OLOPATADINE HYDROCHLORIDE | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Manufacturing (CMC) | ANDA206046 ↗ |
| Jul 29, 2024 | enVista hydrophobic acrylic IOL, enVista toric hydrophobic… intraocular lens | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P910056 ↗ |
| Jul 26, 2024 | Stellaris Elite vision enhancement system (BL11145, BL14455… | BLCO Bausch and Lomb, Incorporated | Device clearance (510(k)) Traditional | K240169 ↗ |
| Jul 25, 2024 | ISTALOL, TIMOLOL MALEATE TIMOLOL MALEATE | BLCO Bausch and Lomb | New drug (NDA), supplement Labeling | NDA021516 ↗ |
| Apr 25, 2024 | BRINZOLAMIDE BRINZOLAMIDE | BLCO Bausch and Lomb | Generic (ANDA), supplement Labeling | ANDA204884 ↗ |
| Apr 19, 2024 | LUMIFY PRESERVATIVE FREE EYE DROPS BRIMONIDINE TARTRATE | BLCO Bausch and Lomb Inc | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA218424 ↗ |
| Apr 4, 2024 | XIIDRA LIFITEGRAST | BLCO Bausch and Lomb Inc | New drug (NDA), supplement Manufacturing (CMC) | NDA208073 ↗ |
| Mar 28, 2024 | Akreos Posterior Chamber Intraocular Lens intraocular lens | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P060022 ↗ |
| Feb 28, 2024 | LUMIFY REDNESS RELIEVER EYE DROPS BRIMONIDINE TARTRATE | BLCO Bausch and Lomb Inc | New drug (NDA), supplement Labeling | NDA208144 ↗ |
| Feb 26, 2024 | Stellaris Elite vision enhancement system | BLCO Bausch and Lomb | Device clearance (510(k)) Traditional | K232084 ↗ |
| Feb 22, 2024 | enVista® Hydrophobic Acrylic Intraocular Lens (IOL) intraocular lens | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P910056 ↗ |
| Jan 12, 2024 | VITRASE HYALURONIDASE | BLCO Bausch and Lomb | Biologic (BLA), supplement Labeling | BLA021640 ↗ |
| Dec 27, 2023 | LATANOPROST LATANOPROST | BLCO Bausch and Lomb | Generic (ANDA), supplement Labeling | ANDA201006 ↗ |
| Aug 21, 2023 | enVista Hydrophobic Acrylic Intraocular Lens intraocular lens | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P910056 ↗ |
| Aug 14, 2023 | DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE | BLCO Bausch and Lomb | Generic (ANDA), supplement Labeling | ANDA090037 ↗ |
| Aug 14, 2023 | DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE | BLCO Bausch and Lomb | Generic (ANDA), supplement Labeling | ANDA090037 ↗ |
| Jul 21, 2023 | NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Labeling | ANDA064135 ↗ |
| Jul 21, 2023 | TOBRAMYCIN AND DEXAMETHASONE DEXAMETHASONE; TOBRAMYCIN | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Labeling | ANDA064134 ↗ |
| Jul 21, 2023 | TOBRAMYCIN AND DEXAMETHASONE DEXAMETHASONE; TOBRAMYCIN | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Labeling | ANDA064134 ↗ |
| Jun 22, 2023 | Amvisc and Amvisc Plus Ophthalmic Viscosurgical Device (OVD) AID, SURGICAL, VISCOELASTIC | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P810025 ↗ |
| Jun 22, 2023 | LEVOBUNOLOL HYDROCHLORIDE LEVOBUNOLOL HYDROCHLORIDE | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Labeling | ANDA074326 ↗ |
| Jun 22, 2023 | LEVOBUNOLOL HYDROCHLORIDE LEVOBUNOLOL HYDROCHLORIDE | BLCO Bausch and Lomb Inc | Generic (ANDA), supplement Labeling | ANDA074326 ↗ |
| May 18, 2023 | MIEBO PERFLUOROHEXYLOCTANE | BLCO Bausch and Lomb Inc | New drug (NDA) Type 1 - New Molecular Entity | NDA216675 ↗ |
| May 2, 2023 | LUMIFY REDNESS RELIEVER EYE DROPS BRIMONIDINE TARTRATE | BLCO Bausch and Lomb Inc | New drug (NDA), supplement Manufacturing (CMC) | NDA208144 ↗ |
| Mar 8, 2023 | Bausch + Lomb (kalifilcon A) Soft (hydrophilic) Contact Len… | BLCO Bausch & Lomb, Incorporated | Device clearance (510(k)) Traditional | K220613 ↗ |
| Dec 6, 2022 | Bausch + Lomb Preservative Free Lubricating and Rewetting D… | BLCO Bausch & Lomb, Incorporated | Device clearance (510(k)) Traditional | K222541 ↗ |
| Sep 23, 2022 | EYE ALLERGY RELIEF, OPCON-A NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE | BLCO Bausch and Lomb | New drug (NDA), supplement Labeling | NDA020065 ↗ |
| Apr 20, 2022 | Soflens 38 (polymacon) Visibility Tinted Contact Lenses Lenses, soft contact, extended wear | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Real-Time Process | N16895 ↗ |
| Apr 8, 2022 | Trulign® Toric Posterior Chamber Intraocular Lens (IOL) Lens, intraocular, accommodative | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P030002 ↗ |
| Mar 18, 2022 | SILSOFT (ELASTOFILCON A) CONTACT LENSES Lenses, soft contact, extended wear | BLCO Bausch & Lomb, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P850068 ↗ |
| Mar 15, 2022 | ATROPINE SULFATE ATROPINE SULFATE | BLCO Bausch and Lomb Inc | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA213581 ↗ |
| Jan 24, 2022 | Eureka! Monthly (samfilcon A) Contact Lenses Lenses, soft contact, extended wear | BLCO Bausch and Lomb, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P170035 ↗ |
| Nov 29, 2021 | LUMIFY REDNESS RELIEVER EYE DROPS BRIMONIDINE TARTRATE | BLCO Bausch and Lomb Inc | New drug (NDA), supplement Labeling | NDA208144 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates